title: The effects of inhaled nitric oxide on the levels of cGMP plasma and lung tissue in a canine model of smoke inhalation injury.
abstract: The effects of inhaled nitric oxide (NO) on pulmonary hypertension and their mechanisms were studied in a canine model of smoke inhalation injury. Twenty-one dogs were randomly divided into three groups: four dogs constituted the normal control group, eight dogs subjected to smoke inhalation followed by O(2) inhalation (FiO(2)=0.45) constituted the injury control group, and nine dogs inhaling a mixture of O(2) and 45ppm nitric oxide after smoke exposure served as the treatment group. The levels of cyclic guanosine monophosphate (cGMP) in arterial plasma of the treatment group were higher than that of the control group at 5, 8, and 12h after smoke exposure, while the levels of cGMP in lung tissue were also significantly higher compared with that of the control group (P<0.01). The levels of cGMP of injury control group were decreased significantly compared with normal controls (P<0.05). Pulmonary vasoconstriction following smoke inhalation was significantly attenuated by inhalation of NO (P<0.05), which exerted no apparent effect on the systemic circulation (P>0.05). Inhalation of NO may lower pulmonary hypertension induced by smoke inhalation injury in dogs. The selective effect of NO on pulmonary circulation may be attributed to an increase in level of cGMP in smooth muscle cells of the lung tissue after inhalation of NO.
authors.affiliation: Center of Burn and Plastic Surgery, Bethune International Peace Hospital, Shi-jia-zhuang, Hebei, PR China. qsz2000@sj-user.he.cninfo.net
authors.forename: Qi
authors.initials: Q
authors.lastname: Shun-Zhen
authors.forename: Zhao
authors.initials: Z
authors.lastname: Hong-Hang
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D006152:Cyclic GMP / Q000032:analysis* / Q000097:blood; D004195:Disease Models, Animal; D004285:Dogs; D006976:Hypertension, Pulmonary / Q000378:metabolism; D008168:Lung / Q000737:chemistry*; D009569:Nitric Oxide / Q000008:administration & dosage*; D009934:Organization and Administration; D010102:Oxygen Inhalation Therapy; D011652:Pulmonary Circulation / Q000187:drug effects; D011897:Random Allocation; D015208:Smoke Inhalation Injury / Q000378:metabolism* / Q000628:therapy
chemical_list: D009569:Nitric Oxide; D006152:Cyclic GMP